According to a report, India’s pharma exports are expected to touch US $ 65 billion by 2030 by 2030 and by 2047 in terms of price of USD 350 billion. While India is the largest supplier of generic drugs globally, accounting for one of the five generic drugs sold worldwide is ranked 11th in terms of nation export price.
According to Ban & Company report, to make ‘Healing the World: Roadmap for India a Global Pharma Exports Hub’, India can potentially secure a position between the top five countries in export price by 2047, with its own. Export baskets can be provided innovation and diversity. Generic, biosimiller and innovative products.
The reports in the report were prepared in collaboration with the Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers Association (IDMA), and Pharxcil.
“In order to secure its right place in the global market, infection is necessary for Indian pharma for a value-based increase from volume-based growth. Innovation, including special generic, biosimiller and novel products, including changes to novel products, the key to the pharmaceutical future of India Will be, “Sriram Shrinivasan, Partner, Ban & Company said. He said that with the right attention to quality, regulation, access to global markets, talent and entrepreneurship innovation, India could be one of the top-five pharma exporters globally by 2047.
National President of the Indian Drug Manufacturers Association (IDMA) Virunchi Shah highlighted that India could become one of the leaders in Pharma exports, but strategic intervention is required. He said that wholesale drug parks are important for API export growth – India should scale efforts to revive and strengthen its API industry by improving energy supply, waste treatment and road connectivity.
Sudarshan Jain, General Secretary of the Pharmaceutical Alliance of India (IPA), said that India aims to become a 30-35 trillion economy by 2047 and to achieve it, the pharmaceutical industry should excel on all fronts.
(Tagstotransite) Pharma (T) PTI
